Clinically significant improvements
An improvement in performance after IR-MPH compared to baseline, and after placebo compared to baseline was considered significant if the Qb-score was decreased ≥ 0.5. A deterioration in performance was considered if the Qb-score was increased ≥ 0.5. The distribution of changes in the cardinal parameters are shown in Table Distribution of changes in Qb-scores for the cardinal parameters (


